Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™

Amsterdam, The Netherlands, January 21, 2013 – Kiadis Pharma B.V., a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing treat­ments for blood can­cers, announced today that it has received a Notice of Allowance for its U.S. Patent Application No. 10/969,011 regard­ing the Company’s lead prod­uct ATIR™. ATIR™ is a cell-based prod­uct that enables stem cell trans­plan­ta­tions from mis­matched donors.
The U.S. patent cov­ers the com­po­si­tion of mat­ter of a rho­damine deriv­a­tive used in man­u­fac­tur­ing ATIR™, all key steps of the man­u­fac­tur­ing process of ATIR™ and the ther­a­peu­tic use of ATIR™ to pre­vent graft-ver­sus-host dis­ease asso­ci­at­ed with allo­gene­ic stem cell trans­plan­ta­tions. Kiadis Pharma has pre­vi­ous­ly been grant­ed sim­i­lar­ly broad patent pro­tec­tion for ATIR™ in Europe.
Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, com­ment­ed: “We are delight­ed about the broad patent pro­tec­tion for ATIR™ in the world’s largest phar­ma­ceu­ti­cal mar­ket. This broad patent pro­tec­tion pro­vides a strong basis for future com­mer­cial­iza­tion of ATIR™ to the ben­e­fit of patients”.
Denis-Claude Roy, MD, Professor of Hematology at the Maisonneuve-Rosemont Hospital and the University of Montreal, and Inventor, added: “ATIR™ has the poten­tial to change the cur­rent par­a­digm in allo­gene­ic stem cell trans­plan­ta­tion for patients with advanced blood can­cers. We are excit­ed that our inven­tion of selec­tive­ly remov­ing patient reac­tive cells from a stem cell dona­tion is being devel­oped by Kiadis Pharma to pre­vent graft-ver­sus-host dis­ease and improve patient out­come”.

Leave a Reply

Your email address will not be published. Required fields are marked *